Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 ...

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) ...
News Medical

New compounds identified as inhibitors of DNA topoisomerase 1

Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential ...
BioWorld

DNA topoisomerase I inhibitors disclosed in Shanghai Yiweikang Pharmaceutical patents

BioWorld - Wednesday, May 28, 2025 Breaking News: 100 days of uncertainty See today's BioWorld Science Home » DNA topoisomerase I inhibitors disclosed in Shanghai Yiweikang Pharmaceutical patents To ...
Nature

Patulin and Xestoquinol are inhibitors of DNA topoisomerase 1

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Medical Xpress

Pharmacologic Actions: News and Research on Topoisomerase Inhibitors

New research published in Nature Communications has linked a normal cellular process to an accumulation of DNA mutations in cancer and identified cancer-driving mutations in an underexplored part of ...
GEN

Making New Connections: Antibody Drug Conjugates Target Cancer

Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...